SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: shero who wrote (3079)5/19/1999 4:23:00 PM
From: Tarken Winn  Read Replies (1) | Respond to of 3702
 
No problem Shero.

Here is a link to the full abstract from ASCO:
asco.org

The TNT abstract is abstract number 550 under "Central Nervous System"

What GregSL posted was correct.

Tarken



To: shero who wrote (3079)5/21/1999 5:29:00 PM
From: GregSL  Read Replies (2) | Respond to of 3702
 
Because of the longer follow-up time, the median time to progression and median survival time were reached. As of 5/7/99 there were four surviving patients. Two with GBM at 30 and 29 weeks. Two with AA at 34 and 45 weeks.

Of the 12 patients, 5 showed stable disease at 9 weeks and 1 showed a partial response at 9 weeks. The partial responder is the AA patient at 34 weeks, and did not show disease progession at the 34 week follow-up visit.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News